Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Catherine Smith, MD

    TitleAssistant Professor
    SchoolUCSF School of Medicine
    Address513 Parnassus Ave
    San Francisco CA 94143
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Duke UniversityM.D.School of Medicine2002

      Collapse Overview 
      Collapse Overview
      My laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. We employ a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows us to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows us to devise ways to circumvent these evolutionary adaptations.

      We have the following specific research focuses at the current time:
      1) Rational discovery and screening of novel FLT3 inhibitors coupled with analysis of resistance mechanisms to clinically relevant FLT3 inhibitors currently in clinical trials.
      2) Identification and validation of non-FLT3 dependent mechanisms of FLT3 inhibitor resistance through genomic analysis of patients treated on FLT3 inhibitor clinical trials.
      3) Study of the role of AML genetic tumor heterogeneity in response and resistance to FLT3 inhibitor therapy.
      4) Understanding the molecular mechanism of recurrent cyclin D3 mutations in mediating resistance to FLT3 inhibitor therapy.

      Collapse Interests
      FLT3, acute myeloid leukemia, drug resistance, CCND3, targeted therapy

      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News
      Collapse Awarded Grants
      Collapse Clinical Trials
      Collapse Featured Publications

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar; 1(3):e85630. PMID: 27158668.
        View in: PubMed
      2. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 Jul; 57(7):1560-6. PMID: 26490487.
        View in: PubMed
      3. Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun; 5(6):668-79. PMID: 25847190; PMCID: PMC4522415.
      4. Frett B, McConnell N, Smith CC, Wang Y, Shah NP, Li HY. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur J Med Chem. 2015 Apr 13; 94:123-31. PMID: 25765758; PMCID: PMC4666306.
      5. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. PMID: 25776193.
        View in: PubMed
      6. Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife. 2014; 3. PMID: 25531068; PMCID: PMC4307180.
      7. Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014 Nov 20; 9(4):1333-48. PMID: 25456130; PMCID: PMC4380442.
      8. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44. PMID: 24894413.
        View in: PubMed
      9. Sudhindra A, Smith CC. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep. 2014 Jun; 9(2):174-85. PMID: 24682858.
        View in: PubMed
      10. Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 8; 111(14):5319-24. PMID: 24623852; PMCID: PMC3986131.
      11. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22. PMID: 24374145; PMCID: PMC4414320.
      12. Smith CC. Disease diversity and FLT3 mutations. Proc Natl Acad Sci U S A. 2013 Dec 24; 110(52):20860-1. PMID: 24324154; PMCID: PMC3876196.
      13. Collins BH, Holzknecht ZE, Lynn KA, Sempowski GD, Smith CC, Liu S, Parker W, Rockey DC. Association of age-dependent liver injury and fibrosis with immune cell populations. Liver Int. 2013 Sep; 33(8):1175-86. PMID: 23710620; PMCID: PMC4151465.
      14. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18; 121(16):3165-71. PMID: 23430109; PMCID: PMC3630831.
      15. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013; 313-8. PMID: 23714533.
        View in: PubMed
      16. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 May 10; 485(7397):260-3. PMID: 22504184; PMCID: PMC3390926.
      17. Smith CC, Shah NP. Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2012; 685-9. PMID: 24451819.
        View in: PubMed
      18. Smith CC, Shah NP. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res. 2011 Nov 1; 17(21):6605-7. PMID: 21948230.
        View in: PubMed
      19. Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011; 2011:121-7. PMID: 22160023.
        View in: PubMed
      20. Kaimal AJ, Smith CC, Laros RK, Caughey AB, Cheng YW. Cost-effectiveness of private umbilical cord blood banking. Obstet Gynecol. 2009 Oct; 114(4):848-55. PMID: 19888044.
        View in: PubMed
      Catherine's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP